Emerging Targets in the Management of Schizophrenia: The Potential of TAAR1 Agonists

Join us for this engaging Master Class session that will provide participants with practical knowledge and skills for managing schizophrenia in clinical practice. The session will begin with a unique poster review before expert faculty dive into the lecture. Grab a headset and take a tour of 3 different posters, each highlighting current data on TAAR1 agonists. The lecture portion of this session will begin by discussing the limitations and barriers associated with the use of antipsychotics for schizophrenia whose MOA centers on dopamine D2 binding. Next, expert faculty will evaluate the mechanism of action and safety/efficacy data associated with TAAR1 agonism in the management of schizophrenia, followed by a discussion of potential clinical implications for TAAR1 agonists and how to identify and educate patients who might benefit from these novel therapies. Don't miss this opportunity to stay up-to-date with the latest advances in schizophrenia treatment and improve outcomes for your patients.

Supported by an independent educational grant from Sunovion Pharmaceuticals Inc. and Otsuka America Pharmaceutical, Inc.